Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 6
Submit an article Journal homepage
149
Views
1
CrossRef citations to date
0
Altmetric
Theme: Hyper- & Hypo-tension - Drug Profile

An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors

Sverre Kjeldsen Department of Cardiology, Ullevål Hospital, N-0407 Oslo, Norway. [email protected]; Department of Cardiology, Ullevål Hospital, N-0407 Oslo, Norway. [email protected]
,
Giuseppe Mancia University of Milano-Bicocca, San Gerardo Hospital, Monza-Milan, Italy; University of Milano-Bicocca, San Gerardo Hospital, Monza-Milan, Italy
,
Roland Schmieder Medizinische Klinik 4, Universitätsklinikum Erlangen, Erlangen, Germany; Medizinische Klinik 4, Universitätsklinikum Erlangen, Erlangen, Germany
,
Michaela Mattheus Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
&
Thomas Unger CARIM – School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands; CARIM – School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands
Pages 673-682 | Published online: 10 Jan 2014

References

  • Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859), 2095–2128 (2012).
  • Sarnak MJ, Levey AS, Schoolwerth AC et al.; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108(17), 2154–2169 (2003).
  • Mancia G, De Backer G, Dominiczak A et al.; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J. Hypertens. 25(9), 1751–1762 (2007).
  • Mancia G, Laurent S, Agabiti-Rosei E et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27(11), 2121–2158 (2009).
  • De Marco M, de Simone G, Izzo R et al. Classes of antihypertensive medications and blood pressure control in relation to metabolic risk factors. J. Hypertens. 30(1), 188–193 (2012).
  • Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch. Intern. Med. 167(2), 141–147 (2007).
  • Chobanian AV, Bakris GL, Black HR et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42(6), 1206–1252 (2003).
  • Bakris G. Are there effects of renin–angiotensin system antagonists beyond blood pressure control? Am. J. Cardiol. 105(1 Suppl.), 21A–29A (2010).
  • Scheen AJ. Renin-angiotensin system inhibition prevents Type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. 30(6), 487–496 (2004).
  • Corrao G, Zambon A, Parodi A et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J. Hypertens. 26(4), 819–824 (2008).
  • Esposti LD, Di Martino M, Saragoni S et al. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J. Clin. Hypertens. (Greenwich) 6(2), 76–84 (2004).
  • Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358(15), 1547–1559 (2008).
  • Taylor AA, Siragy H, Nesbitt S. Angiotensin receptor blockers: pharmacology, efficacy, and safety. J. Clin. Hypertens. (Greenwich) 13(9), 677–686 (2011).
  • Smith DH, Cramer MJ, Neutel JM, Hettiarachchi R, Koval S. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press. Monit. 8(3), 111–117 (2003).
  • Lacourcière Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press. Monit. 9(4), 203–210 (2004).
  • Plosker GL, White WB. Telmisartan/hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension. Drugs 68(13), 1877–1899 (2008).
  • Galzerano D, Capogrosso C, Di Michele S et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc. Health Risk Manag. 6, 113–133 (2010).
  • Burnier M. Telmisartan: a different angiotensin II receptor blocker protecting a different population? J. Int. Med. Res. 37(6), 1662–1679 (2009).
  • Takeda Global Research and Development Centre (Europe) Ltd. Azilsartan medoximil (Edarbi) Summary of Product Characteristics. 6-11-2012.
  • Mallat SG. What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? Cardiovasc. Diabetol. 11, 32 (2012).
  • Simpson SH, Eurich DT, Majumdar SR et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333(7557), 15 (2006).
  • Messerli FH, Makani H, Benjo A, Romero J, Alviar C, Bangalore S. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J. Am. Coll. Cardiol. 57(5), 590–600 (2011).
  • Mancia G, Parati G, Revera M et al. Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial. BMJ 340, c1197 (2010).
  • Zanchetti A, Crepaldi G, Bond MG et al.; PHYLLIS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS – a randomized double-blind trial. Stroke. 35(12), 2807–2812 (2004).
  • Ernst ME, Carter BL, Zheng S, Grimm RH Jr. Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am. J. Hypertens. 23(4), 440–446 (2010).
  • Kjeldsen SE, Schmieder RE, Unger T, Mancia G. Telmisartan and hydrochlorothiazide combination therapy for the treatment of hypertension. Curr. Med. Res. Opin. 26(4), 879–887 (2010).
  • Lacourcière Y, Tytus R, O’Keefe D, Lenis J, Orchard R, Martin K. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J. Hum. Hypertens. 15(11), 763–770 (2001).
  • Lacourcière Y, Martin K. Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension. Am. J. Ther. 9(2), 111–117 (2002).
  • McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin. Ther. 23(6), 833–850 (2001).
  • Zhu DL, Bays H, Gao P, Mattheus M, Voelker B, Ruilope LM. Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial. Clin. Ther. 34(7), 1613–1624 (2012).
  • Lacourcière Y, Gil-Extremera B, Mueller O, Byrne M, Williams L. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int. J. Clin. Pract. 57(4), 273–279 (2003).
  • Neutel JM, Littlejohn TW, Chrysant SG, Singh A; Telmisartan Study Group. Telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens. Res. 28(7), 555–563 (2005).
  • Lacourcière Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin. Ther. 27(11), 1795–1805 (2005).
  • Fogari R, Zoppi A, Mugellini A et al. Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study. Curr. Ther. Res. 69(1), 1–15 (2008).
  • White WB, Murwin D, Chrysant SG, Koval SE, Davidai G, Guthrie R. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Press. Monit. 13(1), 21–27 (2008).
  • White WB, Punzi HA, Murwin D, Koval SE, Davidai G, Neutel JM. Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. J. Clin. Hypertens. (Greenwich) 8(9), 626–633 (2006).
  • Nixon RM, Müller E, Lowy A, Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int. J. Clin. Pract. 63(5), 766–775 (2009).
  • Zhu D, Bays H, Gao P, Mattheus M, Voelker B, Ruilope L. Efficacy and tolerability of a single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg according to age, sex, race, hypertension severity and previous antihypertensive use: planned analyses of a randomized trial. Integr. Blood Press. Control 6, 1–14 (2013).
  • Neldam S, Schumacher H, Guthrie R. Telmisartan 80 mg/hydrochlorothiazide 25 mg provides clinically relevant blood pressure reductions across baseline blood pressures. Adv. Ther. 29(4), 327–338 (2012).
  • Marfatia R, White WB, Schumacher H. Effects of telmisartan with hydrochlorothiazide versus valsartan with hydrochlorothiazide in patients with moderate-to-severe hypertension. Int. J. Hypertens. 2012, 976828 (2012).
  • Takagi H, Mizuno Y, Goto SN, Umemoto T; for ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Overview of telmisartan for blood pressure reduction among angiotensin II receptor blockers: a meta-analysis of head-to-head randomized trials. Int. J. Cardiol. doi:10.1016/j.ijcard.2012.11.086 (2012) (Epub ahead of print).
  • Neldam S, Edwards C; Telmisartan/Hydrochlorothiazide Investigators. Results of increasing doses of hydrochlorothiazide in combination with an angiotensin receptor blocker in patients with uncontrolled hypertension. J. Clin. Hypertens. (Greenwich) 10(8), 612–618 (2008).
  • Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet 380(9841), 601–610 (2012).
  • Bays H, Gao P, Voelker B, Mattheus M, Ruilope L, Zhu D. Efficacy of single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg in patients with cardiovascular disease risk factors: a prospective subgroup analysis of a randomized, double-blind, controlled trial. Int. J. Hypertens 3(6) 1–14 (2013).
  • Neldam S, Edwards C; ATHOS Study Group. Telmisartan plus HCTZ vs amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am. J. Geriatr. Cardiol. 15(3), 151–160 (2006).
  • Kjeldsen SE, Schumacher H, Neldam S, Guthrie RM. Telmisartan/hydrochlorothiazide combination therapy for the treatment of hypertension: a pooled analysis in older and younger patients. J. Clin. Hypertens doi:10.1111jch.12089 (2013) (Epub ahead of print).
  • Boehringer Ingelheim GmBH. MICARDIS® Summary of Product Characteristics. 3-1-2012.
  • Boehringer Ingelheim GmBH. MicardisPlus® Summary of Product Characteristics. 3-6-2013.
  • Hamada T, Mizuta E, Kondo T et al. Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients. Arzneimittelforschung 60(2), 71–75 (2010).
  • Minami J, Furukata S, Ishimitsu T, Matsuoka H. Comparison of therapies between fixed-dose telmisartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild to moderate hypertension. Int. Heart J. 50(1), 85–93 (2009).
  • Sharma AM, Davidson J, Koval S, Lacourcière Y. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with Type 2 diabetes: the SMOOTH study. Cardiovasc. Diabetol. 6, 28 (2007).
  • Jordan J, Yumuk V, Schlaich M et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J. Hypertens. 30(6), 1047–1055 (2012).
  • Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 97(18), 1837–1847 (1998).
  • Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press. Suppl. 1, 32–40 (2008).
  • Greathouse MK, Weir MR. The role of ARBs alone or with HCTZ in the treatment of hypertension and prevention of cardiovascular and renal complications. Postgrad. Med. 124(2), 40–52 (2012).
  • Patel A, MacMahon S, Chalmers J et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370(9590), 829–840 (2007).
  • PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358(9287), 1033–1041 (2001).
  • Peters R, Beckett N, Forette F et al.; HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 7(8), 683–689 (2008).
  • McAlister FA; Renin Angiotension System Modulator Meta-Analysis Investigators. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. Eur. Heart J. 33(4), 505–514 (2012).
  • van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158,998 patients. Eur. Heart J. 33(16), 2088–2097 (2012).
  • Savarese G, Costanzo P, Cleland JG et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J. Am. Coll. Cardiol. 61(2), 131–142 (2013).
  • Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 342, d2234 (2011).
  • Yusuf S, Teo K, Anderson C et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372(9644), 1174–1183 (2008).
  • Suksomboon N, Poolsup N, Prasit T. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. J. Clin. Pharm. Ther. 37(3), 319–327 (2012).
  • Schmieder RE, Bakris G, Weir MR. Telmisartan in incipient and overt diabetic renal disease. J. Nephrol. 24(3), 263–273 (2011).
  • Unger T. Preclinical and clinical effects of RAS inhibition with a focus on telmisartan. ISRN Vasc. Med. 2012 (2012).
  • Galzerano D, Di Michele S, Paolisso G et al. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. J. Renin. Angiotensin. Aldosterone. Syst. 13(4), 496–503 (2012).
  • Verdecchia P, Angeli F, Gentile G, Mazzotta G, Reboldi G. Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev. Clin. Pharmacol. 4(2), 151–161 (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.